{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:00:06Z","timestamp":1789052406380,"version":"build-2803163510"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Italian Medicines Agency","doi-asserted-by":"crossref","award":["J85I2000009005"],"award-info":[{"award-number":["J85I2000009005"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Maintenance immunosuppressive therapy used in kidney transplantation typically involves calcineurin inhibitors, such as tacrolimus or cyclosporine, in combination with mycophenolate or mechanistic target of rapamycin (mTORi) with or without corticosteroids. An Italian retrospective multicentre observational study was conducted to investigate the risk-benefit profile of different immunosuppressive regimens. We identified all subjects who underwent kidney transplant between 2009 and 2019, using healthcare claims data. Patients on cyclosporine and tacrolimus-based therapies were matched 1:1 based on propensity score, and effectiveness and safety outcomes were compared using Cox models (HR; 95%CI). Analyses were also conducted comparing mTORi versus mycophenolate among tacrolimus-treated patients. Patients treated with cyclosporine had a higher risk of rejection or graft loss (HR:1.69; 95%CI:1.16\u20132.46) and a higher incidence of severe infections (1.25;1.00\u20131.55), but a lower risk of diabetes (0.66;0.47\u20130.91) compared to those treated with tacrolimus. Among tacrolimus users, mTORi showed non-inferiority to MMF in terms of mortality (1.01;0.68\u20131.62), reject\/graft loss (0.61;0.36\u20131.04) and severe infections (0.76;0.56\u20131.03). In a real-life setting, tacrolimus-based immunosuppressive therapy appeared to be superior to cyclosporine in reducing rejection and severe infections, albeit with an associated increased risk of diabetes. The combination of tacrolimus and mTORi may represent a valid alternative to the combination with mycophenolate, although further studies are needed to confirm this finding.<\/jats:p>","DOI":"10.1371\/journal.pone.0295205","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T14:27:17Z","timestamp":1704205637000},"page":"e0295205","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness and safety of immunosuppressive regimens used as maintenance therapy in kidney transplantation: The CESIT study"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4558-0921","authenticated-orcid":true,"given":"Arianna","family":"Bellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Finocchietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Cesare","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Nordio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Ferroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Spila Alegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Masiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Bedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cardillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersilia","family":"Lucenteforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Pierobon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ledda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Garau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Davoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Addis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8286-443X","authenticated-orcid":true,"given":"Valeria","family":"Belleudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of CESIT study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"issue":"7","key":"pone.0295205.ref001","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfx074","article-title":"Immunosuppressive agents in adult kidney transplantation in the National Health Service: A model-based economic evaluation","volume":"32","author":"TM Snowsill","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"key":"pone.0295205.ref002","author":"PF Halloran","year":"2004","journal-title":"Immunosuppressive Drugs for Kidney Transplantation."},{"key":"pone.0295205.ref003","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients.","volume":"9","author":"KU Eckardt","year":"2009","journal-title":"American Journal of Transplantation"},{"key":"pone.0295205.ref004","author":"National Institute for Health and Care Excellence (NICE).","year":"2017","journal-title":"Immunosuppressive Therapy for Kidney Transplant in Adults.;"},{"issue":"S2","key":"pone.0295205.ref005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ajt.16502","article-title":"OPTN\/SRTR 2019 Annual Data Report: Kidney.","volume":"21","author":"A Hart","year":"2021","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"pone.0295205.ref006","doi-asserted-by":"crossref","DOI":"10.1016\/j.tpr.2020.100061","article-title":"Immunosuppressive regimens following kidney transplantation in five European countries: The observational RECORD study.","volume":"5","author":"M Arnol","year":"2020","journal-title":"Transplantation Reports"},{"key":"pone.0295205.ref007","first-page":"2005","article-title":"Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients","volume":"19","author":"AC Webster","journal-title":"Cochrane Database of Systematic Reviews. Published online October"},{"key":"pone.0295205.ref008","volume":"29","author":"A Azarfar","year":"2018","journal-title":"Comparison of Tacrolimus and Cyclosporine for Immunosuppression after Renal Transplantation: An Updated Systematic Review and Meta-Analysis"},{"issue":"12","key":"pone.0295205.ref009","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1097\/01.TP.0000069831.76067.22","article-title":"Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: Results at three years","volume":"75","author":"T Gonwa","year":"2003","journal-title":"Transplantation"},{"issue":"4","key":"pone.0295205.ref010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00007890-200208270-00013","article-title":"Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: A prospective multicenter, randomized study","volume":"74","author":"S Sadek","year":"2002","journal-title":"Transplantation"},{"issue":"6","key":"pone.0295205.ref011","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"HT Silva","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"pone.0295205.ref012","first-page":"244","article-title":"Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter","volume":"80","author":"MI Lorber","year":"2005","journal-title":"Phase III Study. Transplantation"},{"issue":"8","key":"pone.0295205.ref013","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/phar.2716","article-title":"Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation.","volume":"42","author":"J Nelson","year":"2022","journal-title":"Pharmacotherapy"},{"key":"pone.0295205.ref014","first-page":"13","article-title":"An Italian multicentre distributed data research network to study the use, effectiveness, and safety of immunosuppressive drugs in transplant patients: Framework and perspectives of the CESIT project.","author":"V Belleudi","year":"2022","journal-title":"Front Pharmacol."},{"key":"pone.0295205.ref015","first-page":"1","article-title":"Temporal and spatial variability of immunosuppressive therapies in transplant patients: An observational study in Italy.","author":"ML Marino","year":"2023","journal-title":"Frontiers in Transplantation"},{"key":"pone.0295205.ref016","volume":"1","author":"M Massari","year":"2020","journal-title":"Istituto Superiore Di Sanit\u00e0 \u201cTheShinISS\u201d: Un Applicativo Open-Source per La Conduzione Di Analisi Distribuite in Studi Di Farmacoepidemiologia Di Tipo Multi-Database."},{"issue":"6","key":"pone.0295205.ref017","first-page":"611","article-title":"Infections in the first year after renal transplant.","volume":"80","author":"EJ Saad","year":"2020","journal-title":"Infecciones en el primer a\u00f1o post-trasplante renal. Medicina (B Aires)."},{"issue":"6","key":"pone.0295205.ref018","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.transproceed.2015.04.087","article-title":"Accuracy of Inpatient International Classification of Diseases, Ninth Revision, Clinical Modification Coding for Cytomegalovirus After Kidney Transplantation","volume":"47","author":"CA Santos","year":"2015","journal-title":"Transplant Proc"},{"issue":"1","key":"pone.0295205.ref019","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ajt.16106","article-title":"Characterizing the landscape and impact of infections following kidney transplantation","volume":"21","author":"KR Jackson","year":"2021","journal-title":"Am J Transplant"},{"issue":"2","key":"pone.0295205.ref020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.15971020","article-title":"Long-Term Infectious Complications of Kidney Transplantation","volume":"17","author":"A Agrawal","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"pone.0295205.ref021","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1093\/ndt\/gfr156","article-title":"Tuberculosis following kidney transplantation: clinical features and outcome.","volume":"26","author":"E Canet","year":"2011","journal-title":"A French multicentre experience in the last 20 years. Nephrol Dial Transplant"},{"issue":"1","key":"pone.0295205.ref022","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The Central Role of the Propensity Score in Observational Studies for Causal Effects","volume":"70","author":"P. R. Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"pone.0295205.ref023","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrneph.2014.159","article-title":"Donor-derived infection\u2014the challenge for transplant safety.","volume":"10","author":"J. Fishman","year":"2014","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"pone.0295205.ref024","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s40620-020-00775-4","article-title":"Donor-transmitted cancer in kidney transplant recipients: a systematic review","volume":"33","author":"A Eccher","year":"2020","journal-title":"J Nephrol"},{"issue":"25","key":"pone.0295205.ref025","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"H Ekberg","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0295205.ref026","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/ndt\/gfh739","article-title":"Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.","volume":"20","author":"BK Kr\u00e4mer","year":"2005","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"pone.0295205.ref027","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0041-1345(02)02960-3","article-title":"Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in kidney transplantation: Twelve-month follow-up","volume":"34","author":"G Montagnino","year":"2002","journal-title":"Transplant Proc"},{"issue":"12","key":"pone.0295205.ref028","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1432-2277.2009.00937.x","article-title":"Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study","volume":"22","author":"A Demirbas","year":"2009","journal-title":"Transpl Int"},{"issue":"3","key":"pone.0295205.ref029","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00467-001-0795-9","article-title":"Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation","volume":"17","author":"R Trompeter","year":"2002","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"pone.0295205.ref030","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1097\/MJT.0000000000000150","article-title":"Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation.","volume":"23","author":"JY Liu","year":"2016","journal-title":"Am J Ther"},{"issue":"6","key":"pone.0295205.ref031","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17061974","article-title":"Effectiveness of Maintenance Immunosuppression Therapies in a Matched-Pair Analysis Cohort of 16 Years of Renal Transplant in the Brazilian National Health System.","volume":"17","author":"RM Gomes","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"pone.0295205.ref032","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1600-6143.2007.01749.x","article-title":"Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus","volume":"7","author":"F Vincenti","year":"2007","journal-title":"Am J Transplant"},{"issue":"2","key":"pone.0295205.ref033","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1432-2277.2009.00955.x","article-title":"Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.","volume":"23","author":"YJ Lee","year":"2010","journal-title":"Transpl Int."},{"issue":"4","key":"pone.0295205.ref034","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1600-6143.2003.00372.x","article-title":"New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis","volume":"4","author":"O Heisel","year":"2004","journal-title":"Am J Transplant"},{"issue":"3","key":"pone.0295205.ref035","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1600-6143.2007.01661.x","article-title":"One-year results with extended-release tacrolimus\/MMF, tacrolimus\/MMF and cyclosporine\/MMF in de novo kidney transplant recipients.","volume":"7","author":"HT Silva","year":"2007","journal-title":"Am J Transplant"},{"issue":"7","key":"pone.0295205.ref036","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073422","article-title":"Diabetes and Cardiovascular Risk in Renal Transplant Patients.","volume":"22","author":"J Rysz","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9768","key":"pone.0295205.ref037","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"K Budde","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"pone.0295205.ref038","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"FP Schena","year":"2009","journal-title":"Transplantation"},{"issue":"7","key":"pone.0295205.ref039","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/ajt.14186","article-title":"Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial.","volume":"17","author":"JW de Fijter","year":"2017","journal-title":"Am J Transplant"},{"issue":"2","key":"pone.0295205.ref040","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/tri.12228","article-title":"The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study.","volume":"27","author":"F M\u00fchlbacher","year":"2014","journal-title":"Transpl Int"},{"issue":"6","key":"pone.0295205.ref041","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.transproceed.2013.03.025","article-title":"A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients","volume":"45","author":"WO Bechstein","year":"2013","journal-title":"Transplant Proc"},{"issue":"1","key":"pone.0295205.ref042","article-title":"mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.","volume":"16","author":"X Xie","year":"2015","journal-title":"BMC Nephrol."},{"issue":"5","key":"pone.0295205.ref043","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/ajt.14090","article-title":"Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.","volume":"17","author":"Y Qazi","year":"2017","journal-title":"Am J Transplant."},{"issue":"7","key":"pone.0295205.ref044","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation","volume":"29","author":"J Pascual","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"pone.0295205.ref045","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40620-019-00675-2","article-title":"Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice","volume":"33","author":"D Cucchiari","year":"2020","journal-title":"J Nephrol"},{"issue":"11","key":"pone.0295205.ref046","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2011.03674.x","article-title":"Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials.","volume":"11","author":"DC Brennan","year":"2011","journal-title":"Am J Transplant"},{"issue":"3","key":"pone.0295205.ref047","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1517\/14740338.2016.1132698","article-title":"Safety of mTOR inhibitors in adult solid organ transplantation","volume":"15","author":"P Ventura-Aguiar","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"pone.0295205.ref048","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2006.11.023","article-title":"Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM.","volume":"195","author":"Y Gou\u00ebffic","year":"2007","journal-title":"Atherosclerosis"},{"issue":"1","key":"pone.0295205.ref049","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40620-019-00609-y","article-title":"Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review.","volume":"33","author":"E Paoletti","year":"2020","journal-title":"J Nephrol"},{"key":"pone.0295205.ref050","article-title":"mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy","volume":"102","author":"2S Suppl 1","year":"2018","journal-title":"Transplantation"},{"issue":"8","key":"pone.0295205.ref051","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41581-018-0022-6","article-title":"Cancer in kidney transplant recipients","volume":"14","author":"E Au","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"pone.0295205.ref052","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/TP.0b013e3182247ae2","article-title":"Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial","volume":"92","author":"J Alber\u00fa","year":"2011","journal-title":"Transplantation"},{"issue":"9","key":"pone.0295205.ref053","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/cam4.487","article-title":"Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis","volume":"4","author":"EL Yanik","year":"2015","journal-title":"Cancer Med"},{"key":"pone.0295205.ref054","first-page":"349","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","author":"GA Knoll","year":"2014","journal-title":"BMJ"},{"issue":"5","key":"pone.0295205.ref055","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1600-6143.2012.04004.x","article-title":"Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer","volume":"12","author":"SB Campbell","year":"2012","journal-title":"Am J Transplant"},{"issue":"4","key":"pone.0295205.ref056","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"S Euvrard","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0295205.ref057","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2012.45.6376","article-title":"Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus","volume":"31","author":"JM Hoogendijk-van Den Akker","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0295205.ref058","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/01.TP.0000151630.25127.3A","article-title":"Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1","volume":"79","author":"E Mah\u00e9","year":"2005","journal-title":"Transplantation"},{"key":"pone.0295205.ref059","article-title":"Comparison of Sirolimus vs.","author":"JF Valente","journal-title":"Mycophenolate Mofetil on Surgical Complications and Wound Healing in Adult Kidney Transplantation"},{"key":"pone.0295205.ref060","article-title":"Immunosuppressive Minimization Strategies in Kidney Transplantation.","author":"J Andrade-Sierra","journal-title":"Organ Donation and Transplantation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T14:28:10Z","timestamp":1704205690000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295205"}},"subtitle":[],"editor":[{"given":"Yavuz","family":"Ayar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0295205","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]}}}